Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Britain drug-cost watchdog says it will recommend Lilly obesity drug
07:06pm, Wednesday, 04'th Dec 2024
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health sys
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
02:41pm, Wednesday, 04'th Dec 2024
Eli Lilly and Company shared data today seemingly confirming the superior weight loss qualities of its tirzepatide GLP-1 agonist over semaglutide from rival Novo Nordisk A/S. Eli Lilly and Novo Nordis
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
12:06pm, Wednesday, 04'th Dec 2024
Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednesday
Stock Of The Day: Where Will The Eli Lilly Rally End?
11:47am, Wednesday, 04'th Dec 2024
Shares of Eli Lilly and Company LLY are trading higher on Wednesday. The company said that its Zepbound drug was more effective in helping adults with obesity lose weight than Novo Nordisk A/S's NVO
Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial
11:41am, Wednesday, 04'th Dec 2024
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zep
Eli Lilly Touts Upbeat Weight-Loss Drug Results
11:00am, Wednesday, 04'th Dec 2024
The weight-loss drug market is about to get even more crowded.
Eli Lilly's stock rises as Zepbound weight-loss drug achieves a key goal
07:24am, Wednesday, 04'th Dec 2024
Zepbound helped patients lose more weight than a major rival in a head-to-head trial.
Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds
07:15am, Wednesday, 04'th Dec 2024
On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
07:10am, Wednesday, 04'th Dec 2024
The magic isn't over for Eli Lilly (LLY 1.69%). Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has plenty of fuel for growth.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
06:52am, Wednesday, 04'th Dec 2024
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-deman
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
06:45am, Wednesday, 04'th Dec 2024
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings sugge
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
06:45am, Wednesday, 04'th Dec 2024
Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 re
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
09:16am, Tuesday, 03'rd Dec 2024
The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's AMGN new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight
Fmr. FDA Commissioner on how Trump could impact GLP-1 industry
06:03pm, Monday, 02'nd Dec 2024
Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger
07:00am, Saturday, 30'th Nov 2024
Data from their most serious competitor, Amgen, suggests the biotech won't upstage the market leaders.
